{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T23:41:11Z","timestamp":1649115671881},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"DOI":"10.1093\/cid\/ciaa1253","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T19:09:58Z","timestamp":1597950598000},"page":"e1669-e1672","source":"Crossref","is-referenced-by-count":1,"title":["Impact of a Meningococcal Protein-based Serogroup B Vaccine on Serogroup W Invasive Disease in Children"],"prefix":"10.1093","volume":"73","author":[{"given":"Helen S","family":"Marshall","sequence":"first","affiliation":[{"name":"Robinson Research Institute and Department of Paediatrics, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia"},{"name":"Department of Paediatrics, Women\u2019s and Children\u2019s Health Network, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C J","family":"Maiden","sequence":"additional","affiliation":[{"name":"Department of Zoology, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"2021100522322872400_CIT0001","doi-asserted-by":"crossref","first-page":"B64","DOI":"10.1016\/j.vaccine.2009.04.061","article-title":"Meningococcal carriage and disease","volume":"27 Suppl 2","author":"Caugant","year":"2009","journal-title":"Vaccine"},{"key":"2021100522322872400_CIT0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"2021100522322872400_CIT0003","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(99)00252-4","article-title":"Meningococcal conjugate vaccines: new opportunities and new challenges","volume":"354","author":"Maiden","year":"1999","journal-title":"Lancet"},{"key":"2021100522322872400_CIT0004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jinf.2015.07.007","article-title":"Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage","volume":"71","author":"Lucidarme","year":"2015","journal-title":"J Infect"},{"key":"2021100522322872400_CIT0005","doi-asserted-by":"crossref","first-page":"20120147","DOI":"10.1098\/rstb.2012.0147","article-title":"The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?","volume":"368","author":"Maiden","year":"2013","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2021100522322872400_CIT0006","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"2021100522322872400_CIT0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/XEB.0000000000000048","article-title":"Control of invasive meningococcal disease: is it achievable?","volume":"14","author":"Marshall","year":"2016","journal-title":"Int J Evid Based Healthc"},{"key":"2021100522322872400_CIT0008","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"2021100522322872400_CIT0009","doi-asserted-by":"crossref","first-page":"e00566-16","DOI":"10.1128\/CVI.00566-16","article-title":"Recent progress in the prevention of serogroup B meningococcal disease","volume":"24","author":"Feavers","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2021100522322872400_CIT0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W strain, England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2021100522322872400_CIT0011","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"2021100522322872400_CIT0012","article-title":"First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England","author":"Ladhani","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021100522322872400_CIT0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/archdischild-2015-308928","article-title":"Enter B and W: two new meningococcal vaccine programmes launched","volume":"101","author":"Ladhani","year":"2016","journal-title":"Arch Dis Child"},{"key":"2021100522322872400_CIT0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"2021100522322872400_CIT0015","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20 Suppl 1","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"2021100522322872400_CIT0016","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"2021100522322872400_CIT0017","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"2021100522322872400_CIT0018","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in chad: a community study [corrected]","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"2021100522322872400_CIT0019","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"2021100522322872400_CIT0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","article-title":"The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease","volume":"11","author":"Zlotnick","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2021100522322872400_CIT0021","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"},{"key":"2021100522322872400_CIT0022","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/cid\/ciz767","article-title":"Genomic characterization of recent and historic meningococcal serogroup E invasive disease in Australia: a case series","volume":"70","author":"Thangarajah","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1253\/33881060\/ciaa1253.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1669\/40511755\/ciaa1253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1669\/40511755\/ciaa1253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T23:12:17Z","timestamp":1633734737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/7\/e1669\/5897487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,8,26]]},"published-print":{"date-parts":[[2021,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1253","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,8,26]]}}}